Yamaguchi T et al., 2021-06-17: A Japanese case report: an 80-year-old woman on pembrolizumab for advanced NSCLC developed severe liver injury after a month of self-administered fenbendazole taken on the basis of social-media reports; her liver tests normalised after she stopped it and she had no tumour shrinkage.
An interview with her and her family revealed that she had been taking fenbendazole for a month, solely based on social media reports suggesting its effectiveness against cancer.
Yamaguchi T et al., 2021-06-17: A Japanese case report: an 80-year-old woman on pembrolizumab for advanced NSCLC developed severe liver injury after a month of self-administered fenbendazole taken on the basis of social-media reports; her liver tests normalised after she stopped it and she had no tumour shrinkage. C8. Study type: case report; N=1; country Japan (Nagoya University Hospital); self-administered fenbendazole, dose/route/schedule not stated in the abstract; concurrent pembrolizumab monotherapy; funder/conflicts not stated in the PubMed record; maker not stated. Correction: the prompt's lead 'Yamaguchi T et al., Intern Med 2021' is wrong on the journal – the paper is Case Reports in Oncology 2021;14:886-891, PMID 34248555. Also filed as FBD-08, FBE-24, FBC-47 (claims C2, C3, C8). Study type: case report.
